165 related articles for article (PubMed ID: 32406289)
21. Methodology used in safety pharmacology: appraisal of the state-of-the-art, the regulatory issues and new directions.
Pugsley MK
J Pharmacol Toxicol Methods; 2005; 52(1):1-5. PubMed ID: 15982903
[TBL] [Abstract][Full Text] [Related]
22. Drug induced shortening of the QT/QTc interval: an emerging safety issue warranting further modelling and evaluation in drug research and development?
Holbrook M; Malik M; Shah RR; Valentin JP
J Pharmacol Toxicol Methods; 2009; 59(1):21-8. PubMed ID: 18834945
[TBL] [Abstract][Full Text] [Related]
23. Methods of collecting and evaluating non-clinical cardiac electrophysiology data in the pharmaceutical industry: results of an international survey.
Hammond TG; Carlsson L; Davis AS; Lynch WG; MacKenzie I; Redfern WS; Sullivan AT; Camm AJ
Cardiovasc Res; 2001 Mar; 49(4):741-50. PubMed ID: 11230973
[TBL] [Abstract][Full Text] [Related]
24. Overview of safety pharmacology.
Porsolt RD
Curr Protoc Pharmacol; 2006 Apr; Chapter 10():Unit10.1. PubMed ID: 22294166
[TBL] [Abstract][Full Text] [Related]
25. A tutorial on model informed approaches to cardiovascular safety with focus on cardiac repolarisation.
Cheung SYA; Parkinson J; Wählby-Hamrén U; Dota CD; Kragh ÅM; Bergenholm L; Vik T; Collins T; Arfvidsson C; Pollard CE; Tomkinson HK; Hamrén B
J Pharmacokinet Pharmacodyn; 2018 Jun; 45(3):365-381. PubMed ID: 29736890
[TBL] [Abstract][Full Text] [Related]
26. The West coast regional safety pharmacology society meeting update: Filling translational gaps in safety assessment.
Abi-Gerges N; McMahon C; Vargas H; Sager P; Chui R; Stevens D; Davila J; Schaub JR; Wu JC; Del Rio C; Mathes C; Miller PE; Burns-Naas LA; Ghetti A
J Pharmacol Toxicol Methods; 2019; 98():106582. PubMed ID: 31077805
[TBL] [Abstract][Full Text] [Related]
27. The northeast regional SPS meeting update: Safety pharmacology innovations and applications.
Pannirselvam M; Brabham T; Botchway AW; Hodges DB; Traebert M; Pugsley MK
J Pharmacol Toxicol Methods; 2017; 85():82-86. PubMed ID: 27913272
[TBL] [Abstract][Full Text] [Related]
28. Innovative approaches to cardiovascular safety pharmacology assessment.
Pugsley MK; Winters BR; Koshman YE; Authier S; Foley CM; Hayes ES; Curtis MJ
J Pharmacol Toxicol Methods; 2024 Jun; 128():107533. PubMed ID: 38945308
[TBL] [Abstract][Full Text] [Related]
29. Cardiovascular parameters in anaesthetized guinea pigs: a safety pharmacology screening model.
Hauser DS; Stade M; Schmidt A; Hanauer G
J Pharmacol Toxicol Methods; 2005; 52(1):106-14. PubMed ID: 15961325
[TBL] [Abstract][Full Text] [Related]
30. Scientific review and recommendations on preclinical cardiovascular safety evaluation of biologics.
Vargas HM; Bass AS; Breidenbach A; Feldman HS; Gintant GA; Harmer AR; Heath B; Hoffmann P; Lagrutta A; Leishman D; McMahon N; Mittelstadt S; Polonchuk L; Pugsley MK; Salata JJ; Valentin JP
J Pharmacol Toxicol Methods; 2008; 58(2):72-6. PubMed ID: 18508287
[TBL] [Abstract][Full Text] [Related]
31. Drug safety Africa: An overview of safety pharmacology & toxicology in South Africa.
Guth BD; Grobler AF; Frazier KS; Greiter-Wilke A; Herzyk D; Hough TA; Khan AA; Markert M; Smith JD; Svenson KL; Wells S; Pugsley MK
J Pharmacol Toxicol Methods; 2019; 98():106579. PubMed ID: 31085319
[TBL] [Abstract][Full Text] [Related]
32. Cardiovascular and respiratory safety pharmacology in Göttingen minipigs: Pharmacological characterization.
Authier S; Gervais J; Fournier S; Gauvin D; Maghezzi S; Troncy E
J Pharmacol Toxicol Methods; 2011; 64(1):53-9. PubMed ID: 21570473
[TBL] [Abstract][Full Text] [Related]
33. The shifting landscape of safety pharmacology in 2015.
Pugsley MK; Authier S; Stonerook M; Curtis MJ
J Pharmacol Toxicol Methods; 2015; 75():5-9. PubMed ID: 26055120
[TBL] [Abstract][Full Text] [Related]
34. A tutorial for model-based evaluation and translation of cardiovascular safety in preclinical trials.
Kulesh V; Vasyutin I; Volkova A; Peskov K; Kimko H; Sokolov V; Alluri R
CPT Pharmacometrics Syst Pharmacol; 2024 Jan; 13(1):5-22. PubMed ID: 37950388
[TBL] [Abstract][Full Text] [Related]
35. Overview of safety pharmacology.
Goineau S; Lemaire M; Froget G
Curr Protoc Pharmacol; 2013 Dec; 63():10.1.1-10.1.8. PubMed ID: 24510755
[TBL] [Abstract][Full Text] [Related]
36. Investigational New Drug Enabling Nonclinical Safety Pharmacology Assessment of the Iminosugar UV-4, a Broad-Spectrum Host-Targeted Antiviral Agent.
Shearer J; Wolfe G; Sampath A; Warfield KL; Kaufman B; Ramstedt U; Treston A
Int J Toxicol; 2022; 41(3):201-211. PubMed ID: 35227115
[TBL] [Abstract][Full Text] [Related]
37. Neurofunctional test batteries in safety pharmacology - Current and emerging considerations for the drug development process.
Jackson SJ; Authier S; Brohmann H; Goody SMG; Jones D; Prior H; Rosch A; Traebert M; Tse K; Valentin JP; Milne A
J Pharmacol Toxicol Methods; 2019; 100():106602. PubMed ID: 31238094
[TBL] [Abstract][Full Text] [Related]
38. Safety pharmacology 2023 and implementation of the ICH E14/S7B Q&A guidance document.
Pugsley MK; Koshman YE; Foley CM; Winters BR; Authier S; Curtis MJ
J Pharmacol Toxicol Methods; 2023; 123():107300. PubMed ID: 37524151
[TBL] [Abstract][Full Text] [Related]
39. Challenges in implementing and obtaining acceptance for J-Tpeak assessment as the clinical component of CiPA.
Darpo B; Couderc JP
J Pharmacol Toxicol Methods; 2018; 93():75-79. PubMed ID: 29879475
[TBL] [Abstract][Full Text] [Related]
40. Safety pharmacology--current and emerging concepts.
Hamdam J; Sethu S; Smith T; Alfirevic A; Alhaidari M; Atkinson J; Ayala M; Box H; Cross M; Delaunois A; Dermody A; Govindappa K; Guillon JM; Jenkins R; Kenna G; Lemmer B; Meecham K; Olayanju A; Pestel S; Rothfuss A; Sidaway J; Sison-Young R; Smith E; Stebbings R; Tingle Y; Valentin JP; Williams A; Williams D; Park K; Goldring C
Toxicol Appl Pharmacol; 2013 Dec; 273(2):229-41. PubMed ID: 23732082
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
